Generate Biomedicines, Inc.

GENB Nasdaq SEC CIK 2100782
Follow Generate Biomedicines Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $4.2M −56.2% vs same quarter last year
Net income −$87.7M −63.5% vs same quarter last year
EPS, diluted −$0.68 +65.5% vs same quarter last year
Operating cash flow −$54.9M −13.3% vs same quarter last year
Revenue by quarter
$8.8M
$10.1M
$9.6M
$7.2M
$6.3M
$4.2M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing